Obsidian Therapeutics is pioneering controllable cell and gene therapies to deliver transformative outcomes for patients with intractable diseases. Obsidian’s programs apply our cytoDriveTM technology in cell and gene therapy products to control expression of proteins for enhanced therapeutic efficacy, including our lead program cytoTIL15 engineered to make TILs more effective for more patients.
 
Our aspirations are high, and we’re built to deliver – well-funded with blue chip investors, engaged field-leading advisors, strong partnerships with industry leaders, and a highly experienced, dynamic, innovative and collaborative team, collectively focused on delivering transformative therapies in areas of greatest clinical need.

Located in the heart of Cambridge with a new laboratory facility in Bedford, we’re proud of our diverse talented team and committed to cultivating an environment of inclusion where we strive to instill a strong sense of belonging, and support each Obsidianite to continuously learn and contribute their best work.  We offer competitive salary and benefits, and potential for employee ownership through stock options.

Alexandria Venture Investments

ShangPharma

Amgen Ventures

Atlas Venture

Takeda Ventures

Vertex Ventures

Vertex Ventures HC

Google Ventures

Bristol-Myers Squibb

Samsara BioCapital

Logos Capital

RA Capital Management

Deep Track Capital

Surveyor Capital

TCG Crossover

The Column Group

Obsidian Therapeutics

We are proud to announce that we have closed a $160.5 million #SeriesC #financing. Proceeds will be used to support clinical development of OBX-115 in ongoing trials, including a multicenter trial for patients with metastatic melanoma and non-small cell lung cancer.

The financing rounds was led by new investor, Wellington Management. Additional new investors participating in the financing include Foresite Capital, Janus Henderson Investors, Novo Holdings A/S, Paradigm BioCapital, RTW Investments, funds and accounts advised by T. Rowe Price Associates, Inc., and Woodline Partners LP. Existing investors Atlas Venture, Blue Owl Healthcare Opportunities, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCGX, Samsara BioCapital and Surveyor Capital (a Citadel company) also participated in the financing. 

Read the full announcement here: https://lnkd.in/eExbpjBU

Today our CEO, Madan Jagasia, will be joining advanced therapy leaders from across the industry at Deloitte's NextGen Therapies Industry Working Group meeting at Deloitte University. Madan is participating in the panel titled, “Leading with Impact: a CEO Perspective on Strategy, Innovation, and Growth”. #NextGenTherapies #IWG2024

Check it out: Obsidian’s Justin Dunlevy, MBA will be participating in a panel titled “Approaching Cost Effective Methods to Dismantle Challenges for Phase 1/2 Companies,” at the Supply Chain & Logistics for Cell Therapies Summit in Boston.

Learn more here: https://lnkd.in/eKugZE56


Congratulations to Andres Alvarado, Arman Aksoy, Caroline Code, Mary Gribble, Gauri Kulkarni, Sheyla Mirabal, Michelle Ols, and Mercay Reuter on their recent promotions!  Thank you all for the value you bring every day, we look forward to your continued growth and success!

We’re excited to announce that we are presenting initial clinical data from the ongoing first-in-human study of OBX-115 and preclinical data from our cytoDRiVE® platform demonstrating regulatable cytoTIL15 signal transduction in cis and trans, as well as the ability of a single drug-responsive domain (DRD) to coregulate two cytokines, LIGHT and mbIL15, in tumor-infiltrating lymphocytes (TIL) during #AACR, which will be held April 5-10, 2024 in San Diego, CA.

To learn more about the positive data results, read here: https://lnkd.in/eZW89dsH

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

DNSSEC

Google Maps

WordPress

Chief Medical Officer

Jennifer Ohde

Chief People Officer

Jennifer Peterson

Chief Legal Officer and Corporate Secretary

Lee Giguere

CEO, Board Member

Paul Wotton

Chief Financial Officer

Ryan Daws

Senior Vice President Finance

David Aubuchon

VP Clinical Pharmacology, Toxicology, Quantitative Sciences

Gabriel Helmlinger

Vice President, Analytical Development

Gwen Wilmes

Senior Vice President, Business Development

Kirsten Kester

Senior Vice President, Program Development

Melanie Call

Cariad Chester

Raymond Camahort

Maria Fardis

Steve Shamah

Senior Vice President & Head of Research

Jan Ter Meulen

Jeffrey Trigilio

Parnian Zia-Amirhosseini

VP and Head of Regulatory Affairs & Quality Assurance

Catherine Stehman-Breen

Karen Brown

SVP of Intellectual Property and Legal Affairs

East Coast Late Stage Companies With More Than 10 Employees

Greater Boston Area Startups Founded in 2015

East Coast Pharmaceutical Companies

Northeastern US Companies With Less Than $50M in Revenue (Top 10K)

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Wellington Management

Series C - Obsidian Therapeutics

Series B - Obsidian Therapeutics

Series A - Obsidian Therapeutics

Cambridge

Massachusetts

United States

North America

Obsidian Therapeutics Announces FDA Fast Track Designation for OBX-115 for the Treatment of Advanced Melanoma

The biggest private biotech investments in April 2024

Obsidian Therapeutics’ Post

Obsidian Therapeutics Appoints Jeffrey Trigilio as Chief Financial Officer

Biopharma Company Obsidian Therapeutics Raises $160.5M

Obsidian Therapeutics Secures $160.5M Series C Financing for Innovative Cell Therapy

Obsidian Therapeutics Raises $160.5M in Series C Funding

Obsidian Therapeutics: Cell And Gene Therapies Company Raises $160.5 Million

A technology that controls protein function in cell and gene therapies using drug-responsive domains and FDA-approved small molecules.

A TIL cell therapy genetically modified to produce membrane-bound IL15, eliminating the need for co-administered high-dose IL2 in treating advanced or metastatic melanoma.

India

Asia

Philippines

Bangladesh

Morocco

Africa

HTML5

DigiCert

Microsoft Outlook

Google Maps API

GoDaddy

F5 NGINX

Adobe Fonts

Apache Server

GoDaddy Premium DNS

BeiGene is a biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer.

BeiGene

Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases.

Vir Biotechnology

Hummingbird Bioscience is a biotech company that focuses on developing precision therapies for the treatment of cancer and autoimmune diseases.

Hummingbird Bioscience

Advanced Accelerator Applications is a radiopharmaceutical company that develops, produces, and commercializes molecular nuclear medicine diagnostic and therapeutic products.

Advanced Accelerator Applications

Ultivue is a biotech company specializing in multiplex tissue biomarker assays for tissue biomarker analysis in translational research and clinical diagnostics.

Ultivue

Ohana Biosciences is a biotech company focused on developing novel therapies for reproductive health and fertility.

Ohana Biosciences

Matterworks is a biotech company that specializes in developing advanced materials for various applications in the healthcare and life sciences industries.

Matterworks

Sonoma Biotherapeutics is a biotech company focused on developing innovative cell therapies for the treatment of cancer and autoimmune diseases.

Sonoma Biotherapeutics

Neomorph Inc is a biotech company that specializes in developing novel drug candidates for the treatment of various diseases, with a focus on precision medicine.

Neomorph Inc

Inception Sciences Inc is a biotech company that focuses on discovering and developing novel small molecule and biologic drug candidates for therapeutic applications.

Inception Sciences Inc

SBH Sciences Inc is a biotech company specializing in providing contract research services for the development and testing of biopharmaceutical products.

SBH Sciences Inc

Kriya Therapeutics is a biotech company focused on developing transformative gene therapies for the treatment of genetic and rare diseases.

Kriya Therapeutics

ROME Therapeutics is a biotech company that aims to develop novel therapies targeting the immune system to treat cancer and autoimmune diseases.

ROME Therapeutics

Nkarta Therapeutics is a biotech company focused on developing engineered natural killer (NK) cell therapies for the treatment of cancer.

Nkarta Therapeutics

Navrogen is a biotech company that focuses on developing novel cancer therapies targeting specific genetic mutations and pathways.

Navrogen

CytomX is a biotech company that specializes in developing Probody therapeutics for the treatment of cancer and other serious diseases.

CytomX

NexImmune is a biotech company focused on developing novel T cell therapies for the treatment of cancer and other immune-related diseases.

NexImmune

Obsidian Therapeutics is a biotech company that develops innovative therapies for various diseases. The company is focused on creating novel treatments that can improve patient outcomes and quality of life.

Director Regulatory Affairs CMC

Sr. Manager Regulatory Affairs

Regulatory Affairs Manager

Founder CEO

Chief Editor

Todd Hawley

Director, Quality Assurance, Obsidian Therapeutics

AD Global Quality Compliance

Site head of Quality

Quality Assurance-Department Head

Vaccines and CHO Cell Operation’s Manager

Compliance and Investigation Manager

Eric Gennell

Associate Director Supply Chain, Cell & Gene Therapy

Senior Solutions Owner, Cell & Gene Therapy

Product Owner for Cell & Gene Therapy Supply Chain & Logistics Online Software Platform

news impact assignment basic	general	May 2, 2024 4:55 PM	54bbf677
public peers	general	May 2, 2024 4:55 PM	b59f2bd9
news daily refresh	general	Jul 25, 2024 12:00 PM	b41c299b
news processing daily refresh	general	May 21, 2024 2:23 AM	809ac2f2
news impact assignment daily	general
news processing basic	general	May 2, 2024 4:55 PM	8013eead
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	93271081
crunchbase profile	general	Nov 25, 2024 11:40 AM	20937e6a
li profile	general	May 2, 2024 4:55 PM	3482ddef
translate crunchbase fundingrounds	general	Nov 25, 2024 2:09 PM	23937e1b
peers	general
news basic	general	May 2, 2024 4:55 PM	7f33a9c1
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:OBSIDIANTX

Obsidian Therapeutics, Inc.